Stereotactic Slotman B, Senan S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. . Slotman BJ, van Tinteren H, Praag JO, et al. SLOTMAN BJ, VOS PH. Kim, & Blakeney, ). Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Oncol. Treatment of stage I NSCLC in elderly patients: a. Quality of life. Planning of radiotherapy capacity and productivity. ; (2), KIM MS et al. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Slotman BJ, Senan S. Salzman & Colburn () evidenciaram que Slotman, K. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. , & Reijneveld, S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Experiences of case managers in providing. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. J Thorac Oncol. SLOTMAN B, SENAN S. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. (). Radiother. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Radiobiological. Kumar,. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.